MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.470
+0.130
+3.89%
After Hours: 3.470 0 0.00% 17:48 07/10 EDT
OPEN
3.310
PREV CLOSE
3.340
HIGH
3.480
LOW
3.160
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
6.97
52 WEEK LOW
1.210
MARKET CAP
239.02M
P/E (TTM)
-2.5700
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CBAY stock price target is 9.00 with a high estimate of 15.00 and a low estimate of 6.00.

EPS

CBAY News

More
Is CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Popular Amongst Institutions?
Simply Wall St. · 5d ago
Hedge Funds Keep Selling CymaBay Therapeutics Inc (CBAY)
Insider Monkey · 06/29 00:20
CymaBay: Live And Die By The FDA
Seeking Alpha - Article · 06/25 18:34
CymaBay Seladelpar Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/23 18:32
Inventiva files for IPO
Seeking Alpha - Article · 06/19 21:01
CymaBay up 7% on new seladelpar data in bile duct disorder
Seeking Alpha - Article · 06/19 15:22
CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education
GlobeNewswire · 06/19 13:00
Genfit: Beaten Down But Not Dead
Seeking Alpha - Article · 06/19 01:55

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CBAY

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.
More

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.